Compare FCNCA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCNCA | ILMN |
|---|---|---|
| Founded | 1898 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 20.4B |
| IPO Year | N/A | 2000 |
| Metric | FCNCA | ILMN |
|---|---|---|
| Price | $1,780.01 | $118.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 17 |
| Target Price | ★ $2,199.60 | $124.24 |
| AVG Volume (30 Days) | 105.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 5.45 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $3.43 | $6.52 |
| Revenue Next Year | N/A | $5.49 |
| P/E Ratio | ★ $12.17 | $21.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1,473.62 | $68.70 |
| 52 Week High | $2,232.21 | $155.53 |
| Indicator | FCNCA | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 28.29 | 40.20 |
| Support Level | $1,625.08 | $114.88 |
| Resistance Level | $1,795.17 | $135.68 |
| Average True Range (ATR) | 64.21 | 4.53 |
| MACD | -15.63 | -0.34 |
| Stochastic Oscillator | 0.41 | 19.13 |
First Citizens is a US regional bank with total assets of over $230 billion as of Sept. 30, 2025. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of making troubled bank acquisitions from the FDIC, like the 2023 acquisition of Silicon Valley Bridge Bank, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2024.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.